ONCY News and Press, Oncolytics Biotech Inc. From 11/05/21

Oncolytics Biotech Inc. (ONCY) Q3 2021 Earnings Conference Call November 5, 2021 08:00 ET Company Participants Jon Patton - Director of Investor Relations & Communications Matt Coffey - President, Chief Executive Officer & Director Tom Heineman - Global Head of Clinical Development &a...

Shares of Oncolytics Biotech (NASDAQ:ONCY) are up 8% in premarket trading after the company beat Q3 earnings estimates and released new data on a key breast cancer candidate. Phase 1 biomarker data for pelareorep, its candidate for early breast cancer, indicated that changes in...

Oncolytics Biotech® Reports 2021 Third Quarter Development Highlights and Financial Results Canada NewsWire Clinical breast cancer data indicate pelareorep-induced changes in blood T cell populations may be a predictive biomarker Advanced collaboration wit...

Oncolytics Biotech (NASDAQ:ONCY) is scheduled to announce Q3 earnings results on Thursday, November 4th, after market close. The consensus EPS Estimate is -$0.10 and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. For ...

AMCX,AMR,AXL,BBU,BEP,CGAU,CGC,CLMT,CNK,CNTY,D,DKNG,DOC,DTM,EAF,ELAN,ENB,EOG,ERJ,ESNT,FLR,GCI,OTCPK:GCTAF,GECC,GLP,GOOS,GRPN,GT,HE,HMC,INTT,JCI,KIM,LMRK,MFA,MGA,MITT,NMRK,NOG,NWN,OFS,ONCY,PLYM,PNW,REV,SII,SRE,SSP,SYRS,TEN,TRP,TU,TUSK,VRS,VST,VTR,XELA For Seeking Alpha's full earnings season ca...

Palm Beach, FL – November 3, 2021 – FinancialNewsMedia.com News Commentary – The metastatic cancer treatment systems market is observing high demand attributed to its increasing application in breast, lung, melanoma, prostate, and colorectal cancers. Factors...

Oncolytics Biotech (NASDAQ:ONCY) announces that the first patient has been dosed in the phase 1/2 GOBLET trial. The trial is designed to investigate the use of pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab in patients with metastatic pancreatic, meta...

Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers Canada NewsWire Multi-center trial is being conducted in collaboration with Roche and AIO Trial is design...

FN Media Group Presents USA News Group News Commentary Vancouver, BC –October 14, 2021 – USA News Group –  Compared to the Dow Jones Industrial Average which has gained an impressive 10.6% through Q3 2021, and the S&P 500 and Nasdaq doing ev...

Compared to the Dow Jones Industrial Average which has gained an impressive 10.6% through Q3 2021, and the S&P 500 and Nasdaq doing even better with 14.7% and 12.1% gains respectively, the biotech sector has been lagging behind . The Nasdaq Healthcare Index has only gained 4.2%, whi...